title: The neuroprotective effect of picroside II via regulating the expression of myelin basic protein after cerebral ischemia injury in rats.
abstract: BACKGROUND
  To explore the neuroprotective effect and optimize the therapeutic dose and time window of picroside II by orthogonal test and the expression of myelin basic protein (MBP) in cerebral ischemic injury in rats. Bilateral common carotid artery occlusion (BCCAO) was used to establish forebrain ischemia models. The successful rat models were grouped according to orthogonal experimental design and injected picroside II intraperitoneally at different ischemic time with different doses. Myelin sheath fast green staining(FGS) and transmission electron microscopy (TEM) were used to observe nerve fiber myelin; the expression of MBP was tested qualitatively and quantitatively by immunohistochemical assay (IHC) and Western blot (WB); Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the transcription level of MBP mRNA.
  
  
  RESULTS
  The protective effect of picroside II was presented by increasing the expression of MBP and decreasing demyelination after cerebral ischemic injury. The best therapeutic time window and dose was (1) ischemia 2.0 h with picroside II 10 mg/kg body weight according to the results of FGS, IHC and WB; (2) ischemia 1.5 h with picroside II 20 mg/kg according to the analysis of RT-PCR.
  
  
  CONCLUSIONS
  Given the principle of the longest time window and the lowest therapeutic dose, the optimized therapeutic dose and time window should be injecting picroside II intraperitoneally with 10-20 mg/kg body weight at ischemia 1.5-2.0 h in cerebral ischemic injury.
authors: Li
authors: L
authors: Zhao
authors: Institute of Cerebrovascular Diseases, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China. guoqdsd@163.com.
authors: Yunliang
authors: Y
authors: Guo
authors: Xiaojun
authors: X
authors: Ji
authors: Meizeng
authors: M
authors: Zhang
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000378:metabolism* / Q000517:prevention & control*; D002934:Cinnamates / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D057888:Iridoid Glucosides / Q000008:administration & dosage*; D008297:Male; D004676:Myelin Basic Protein / Q000096:biosynthesis*; D009186:Myelin Sheath / Q000187:drug effects / Q000473:pathology*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
chemical_list: D002934:Cinnamates; D057888:Iridoid Glucosides; D004676:Myelin Basic Protein; D018696:Neuroprotective Agents; C416837:picroside II